Grit Biotechnology secures funds for development of pipeline programmes

2023-09-11

临床1期基因疗法细胞疗法临床2期临床申请

Grit Biotechnology secures funds for development of pipeline programmes

Preview

来源: Pharmaceutical Technology

A tumour-infiltrating lymphocyte therapy of Grit Biotechnology, GT101 is set to enter the Phase II trial by year-end. Credit: CI Photos/Shutterstock.com.

Preview

来源: Pharmaceutical Technology

Cell therapy company Grit Biotechnology has secured more than $60m (436.72m yuan) in a Series B funding round to support the development of its pipeline programmes.

China International Capital Corporation led the financing round, which saw investments from Liando Group, Qianhai Ark, Yuanhe Capital and HeFangTian Venture Partnership.

Recommended Reports

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - ustekinumab biosimilar GlobalData

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - tenecteplase biosimilar GlobalData

View allCompanies IntelligenceChina International Capital Corp LtdMatrix Partners ChinaDecheng Capital LLCYuanhe CapitalGritView all

Grit’s existing investors, namely Sherpa Healthcare Partners, Matrix Partners China and Decheng Capital, also took part in the financing round.

Grit plans to utilise the investment proceeds to support the development of its tumour-infiltrating lymphocyte (TIL) pipeline.

These funds will also be used for the Phase II clinical trial of TIL therapy, GT101, and progress next-gen gene-edited TIL products.

GT101 is set to enter the Phase II trial by year-end.

Grit Biotechnology was established in 2019 and is focused on offering transformative therapies for cancer.

The company uses four technology platforms for developing gene-edited TIL products: StemTexp, StaViral, KOReTIL and genome-wide CRISPR/Cas9 screening platform ImmuT Finder.

Apart from GT101, the company is developing GT201, a genetically engineered TIL product, and a next-gen TIL product, GT316.

GT201 has received new drug application clearance from the China Food and Drug Administration and is currently being evaluated in Phase I trials while GT316 is in investigator-initiated trials in the region.

Grit has a 10,000m² GMP-level cell therapy production facility in Suzhou with a workforce of more than 100 specialists.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free WhitepaperCell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.By Cytiva Thematic

Preview

来源: Pharmaceutical Technology

-->

By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构